Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025 [0.03%]
患者和医师对2025年ASCO上公布的前列腺癌数据的见解
Pedro Barata,Tom Hulsey
Pedro Barata
In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience an...
Burden of Treatment, Treatment Sequencing and Healthcare Resource Utilization in Multiple Myeloma in Latin America: A Targeted Literature Review [0.03%]
南美多发性骨髓瘤患者的治疗负担、治疗顺序及医疗资源利用状况：定向文献回顾结果
Cristian Maximiliano Seehaus,Guillermina Remaggi,Jayr Schmidt Filho et al.
Cristian Maximiliano Seehaus et al.
Approval of key drug classes has improved survival for patients with multiple myeloma (MM). However, most patients experience relapse or become refractory to these treatments, with retreatment having limited efficacy. Access to these key tr...
Definition of Sporadic Early-Onset Invasive Solid Organ Cancers in Adults [0.03%]
成人散发性早发侵袭性实体器官癌的定义
Savio George Barreto,Irit Ben-Aharon,Cathy Eng et al.
Savio George Barreto et al.
With a rising incidence globally, there is need to address a basic deficiency, namely, the lack of a clear definition of sporadic early-onset invasive solid organ cancers in adults. This manuscript discusses this need to have a unified unde...
A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025-Standard and Considerations for an Individualized Treatment [0.03%]
R/M-SCCHN 2025年治疗的播客讨论—标准与个体化治疗的考量
Philipp Ivanyi,Tabea Fröhlich,Jonas Paul Wiegmann et al.
Philipp Ivanyi et al.
Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) remains a disease with limited treatment options. Once salvage surgery or radiotherapy is no longer feasible, systemic medical therapy becomes the mainstay...
Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi Arabia [0.03%]
沙特阿拉伯肿瘤学家关于乳腺癌早期和转移性管理的共识声明
Sabah Alaklabi,Sadal Al Refaei,Omalkhair Abualkhair et al.
Sabah Alaklabi et al.
Introduction: In the Kingdom of Saudi Arabia, there is a lack of up-to-date clinical guidelines on the treatment of early-stage or metastatic breast cancer (BC) that are relevant to local resource and financial constraint...
Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England [0.03%]
纳武利尤单抗联合双联铂类化疗作为英国可切除非小细胞肺癌新辅助治疗的性价比分析
Joel Russell,Mack Harris,Ariel Sun et al.
Joel Russell et al.
Introduction: This study aimed to assess the cost-effectiveness of neoadjuvant nivolumab + platinum doublet chemotherapy (PDC) versus relevant comparators in the treatment of patients with non-metastatic (stage IB-IIIA), ...
Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy [0.03%]
纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌3期CheckMate 9LM研究中整体生存率的两阶段估计及后续治疗影响的调整
Marc-Oliver Grimm,Emma Karim,Venediktos Kapetanakis et al.
Marc-Oliver Grimm et al.
Introduction: The CheckMate 9ER (CM9ER) trial demonstrated the superiority of cabozantinib plus nivolumab (CaboNivo) over sunitinib (SUN) in patients with untreated advanced renal cell carcinoma (aRCC). We conducted a pos...
Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer [0.03%]
真实世界证据和激素受体阳性/her2阴性晚期乳腺癌细胞周期蛋白依赖性激酶4/6抑制剂治疗预后的报告结果研究
Sarah Sammons,Denise A Yardley,Priyanka Sharma et al.
Sarah Sammons et al.
Jing Di,Emmy Mbagwu,Subhasree Basu et al.
Jing Di et al.
Introduction: Prostate-specific membrane antigen (PSMA) is a key diagnostic/prognostic, therapeutic target in prostate cancer. While PSMA expression is well established in prostate cancer, its expression is also observed ...
The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review [0.03%]
膀胱内灌注对非肌层浸润性膀胱癌患者生活质量的影响：系统评价
Ingolf Griebsch,Sunil Shrestha,Yair Lotan et al.
Ingolf Griebsch et al.
Background: Non-muscle invasive bladder cancer (NMIBC) is commonly treated with transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy and/or Bacillus Calmette-Guérin (BCG) instillations. ...